Premium
Anti‐angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis
Author(s) -
Caruthers Shelton D.,
Cyrus Tillmann,
Winter Patrick M.,
Wickline Samuel A.,
Lanza Gregory M.
Publication year - 2009
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.9
Subject(s) - targeted therapy , targeted drug delivery , molecular imaging , drug delivery , medicine , proteomics , drug , nanotechnology , pharmacology , biology , cancer , in vivo , materials science , biochemistry , microbiology and biotechnology , gene
Complementary developments in nanotechnology, genomics, proteomics, molecular biology and imaging offer the potential for early, accurate diagnosis. Molecularly‐targeted diagnostic imaging agents will allow noninvasive phenotypic characterization of pathologies and, therefore, tailored treatment close to the onset. For atherosclerosis, this includes anti‐angiogenic therapy with specifically‐targeted drug delivery systems to arrest the development of plaques before they impinge upon the lumen. Additionally, monitoring the application and effects of this targeted therapy in a serial fashion will be important. This review covers the specific application of α ν β 3 ‐targeted anti‐angiogenic perfluorocarbon nanoparticles in (1) the detection of molecular markers for atherosclerosis, (2) the immediate verification of drug delivery with image‐based prediction of therapy outcomes, and (3) the serial, noninvasive observation of therapeutic efficacy Copyright © 2009 John Wiley & Sons, Inc. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease